Biomarkers · Lipids & Apolipoproteins
Apolipoprotein A1 (ApoA1)
Both low and high values go with higher risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
ApoA1 and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in ApoA1, study by study
2 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| diet | Mediterranean dietary pattern rich in polyphenols and virgin olive oil | Increased ApoA-I by 3.3 mg/dL (95% CI 0.84 to 5.8) vs low-fat diet at 3 months (TMD + virgin olive oil) | RCT | Solá R, et al. Effect of a traditional Mediterranean diet on apolipoproteins B… |
| exercise | Aerobic endurance training and vigorous physical activity | Exercise training raised apolipoprotein A1 vs controls across 160 RCTs (effect size not reported) | meta-analysis | Lin X, et al. Effects of Exercise Training on Cardiorespiratory Fitness and… |
| pharmacologic | Niacin therapy (Extended-release 1000-2000 mg/day) | Increased ApoA1 by 8·23 mg/dl (WMD, meta-analysis of RCTs); effect seen at > 1500 mg/d and greater with extended-release niacin | meta-analysis | Saboori S, et al. Effects of niacin on apo A1 and B levels: a systematic review… |
Things that worsen it
| Type | Condition or exposure | Reported effect | Evidence | Source |
|---|---|---|---|---|
| behavioral | Cigarette smoking and chronic tobacco exposure | Continuing smokers had lower apo A-I than quitters after cessation program (P < .001; effect size not reported) | cohort | Richard F, et al. Effect of smoking cessation on lipoprotein A-I and… |
| clinical | Metabolic syndrome (hypertriglyceridemic dyslipidemia) | ApoA-I significantly lower in adults with MetS vs without MetS (effect size not reported) | cross-sectional | Mattsson N, et al. Metabolic syndrome and carotid intima-media thickness in… |
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Genetic predisposition
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ APOA1 locus rs12225230 · per C allele | +0.076 SD per allele (95% CI 0.051 to 0.101) | per additional C allele of rs12225230 · 20,370 Finnish participants (GWAS of circulating apoA-I) | gwas · PMID 32113648 |
Sources
- Risk curve: Faaborg-Andersen 2023 (PMID 36351048): all-cause HR 1.14 (1.07-1.21) highest decile of ApoA1 (1.91-2.50 g/L) vs lowest-risk eighth decile (1.67-1.75 g/L). Scaled to published population values.
- Faaborg-Andersen et al. U-shaped relationship between apolipoprotein A1 levels and mortality risk in men and women. European journal of preventive cardiology. 2023;30:293-304.
Map Apolipoprotein A1 (ApoA1) against another biomarker.
Related markers: Apolipoprotein B (ApoB) · HDL Cholesterol · LDL Cholesterol · Lipoprotein(a) [Lp(a)] · Remnant Cholesterol · Serum Triglycerides · Total Cholesterol